Dupilumab for Chronic Obstructive Pulmonary Disease: A Systematic Review
<b>Background/Objectives</b>: Dupilumab was recently approved to treat eosinophilic phenotypes of chronic obstructive pulmonary disease (COPD). This systematic review aimed to collect and appraise the efficacy and safety of dupilumab to treat patients with COPD. <b>Methods</b>...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Biologics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-8449/5/1/5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849342040431656960 |
|---|---|
| author | Julia Young Taylor Spisany Corey M. Guidry Jisoo Hong Jessica Le Edward El Rassi Paul M. Boylan |
| author_facet | Julia Young Taylor Spisany Corey M. Guidry Jisoo Hong Jessica Le Edward El Rassi Paul M. Boylan |
| author_sort | Julia Young |
| collection | DOAJ |
| description | <b>Background/Objectives</b>: Dupilumab was recently approved to treat eosinophilic phenotypes of chronic obstructive pulmonary disease (COPD). This systematic review aimed to collect and appraise the efficacy and safety of dupilumab to treat patients with COPD. <b>Methods</b>: Databases searched included Ovid Medline, Embase, Web of Science, Directory of Open Access Journals, and International Pharmaceutical Abstracts. Experimental and observational studies, including case reports/series, were eligible for inclusion. Reports were independently screened, appraised, and extracted by three investigators; disagreements were resolved through discussion and agreement. Quality appraisal was conducted using the Cochrane Risk of Bias Tool 2.0, Newcastle–Ottawa Scale, and JBI Checklist for experimental, observational, and case studies, respectively. <b>Results</b>: A total of 307 unique reports were identified, of which 17 were included in this systematic review. The majority (n = 11, 64.7%) of reports presented evidence from the BOREAS and NOTUS trials, the landmark trials serving as the basis for dupilumab’s approval to treat refractory eosinophilic COPD. The results from this systematic review found that dupilumab reduced exacerbations of COPD in patients treated with inhaled triple therapy and it was well tolerated. <b>Conclusions</b>: When added to inhaled triple therapy, dupilumab may decrease patients’ risk for acute exacerbations of COPD. Additional research is necessary to substantiate these findings for broader generalizability, including populations with non-eosinophilic COPD phenotypes. |
| format | Article |
| id | doaj-art-2157ec9577344a55805d86b0f47aeac9 |
| institution | Kabale University |
| issn | 2673-8449 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biologics |
| spelling | doaj-art-2157ec9577344a55805d86b0f47aeac92025-08-20T03:43:30ZengMDPI AGBiologics2673-84492025-02-0151510.3390/biologics5010005Dupilumab for Chronic Obstructive Pulmonary Disease: A Systematic ReviewJulia Young0Taylor Spisany1Corey M. Guidry2Jisoo Hong3Jessica Le4Edward El Rassi5Paul M. Boylan6College of Pharmacy, The University of Oklahoma Health Sciences, Oklahoma City, OK 73117, USACollege of Pharmacy, The University of Oklahoma Health Sciences, Oklahoma City, OK 73117, USACollege of Pharmacy, The University of Oklahoma Health Sciences, Oklahoma City, OK 73117, USACollege of Pharmacy, The University of Oklahoma Health Sciences, Oklahoma City, OK 73117, USACollege of Pharmacy, The University of Oklahoma Health Sciences, Oklahoma City, OK 73117, USACollege of Medicine, The University of Oklahoma Health Sciences, Oklahoma City, OK 73117, USACollege of Pharmacy, The University of Oklahoma Health Sciences, Oklahoma City, OK 73117, USA<b>Background/Objectives</b>: Dupilumab was recently approved to treat eosinophilic phenotypes of chronic obstructive pulmonary disease (COPD). This systematic review aimed to collect and appraise the efficacy and safety of dupilumab to treat patients with COPD. <b>Methods</b>: Databases searched included Ovid Medline, Embase, Web of Science, Directory of Open Access Journals, and International Pharmaceutical Abstracts. Experimental and observational studies, including case reports/series, were eligible for inclusion. Reports were independently screened, appraised, and extracted by three investigators; disagreements were resolved through discussion and agreement. Quality appraisal was conducted using the Cochrane Risk of Bias Tool 2.0, Newcastle–Ottawa Scale, and JBI Checklist for experimental, observational, and case studies, respectively. <b>Results</b>: A total of 307 unique reports were identified, of which 17 were included in this systematic review. The majority (n = 11, 64.7%) of reports presented evidence from the BOREAS and NOTUS trials, the landmark trials serving as the basis for dupilumab’s approval to treat refractory eosinophilic COPD. The results from this systematic review found that dupilumab reduced exacerbations of COPD in patients treated with inhaled triple therapy and it was well tolerated. <b>Conclusions</b>: When added to inhaled triple therapy, dupilumab may decrease patients’ risk for acute exacerbations of COPD. Additional research is necessary to substantiate these findings for broader generalizability, including populations with non-eosinophilic COPD phenotypes.https://www.mdpi.com/2673-8449/5/1/5dupilumabinterleukin 4interleukin 13eosinophiliachronic obstructive pulmonary diseasetype 2 inflammation |
| spellingShingle | Julia Young Taylor Spisany Corey M. Guidry Jisoo Hong Jessica Le Edward El Rassi Paul M. Boylan Dupilumab for Chronic Obstructive Pulmonary Disease: A Systematic Review Biologics dupilumab interleukin 4 interleukin 13 eosinophilia chronic obstructive pulmonary disease type 2 inflammation |
| title | Dupilumab for Chronic Obstructive Pulmonary Disease: A Systematic Review |
| title_full | Dupilumab for Chronic Obstructive Pulmonary Disease: A Systematic Review |
| title_fullStr | Dupilumab for Chronic Obstructive Pulmonary Disease: A Systematic Review |
| title_full_unstemmed | Dupilumab for Chronic Obstructive Pulmonary Disease: A Systematic Review |
| title_short | Dupilumab for Chronic Obstructive Pulmonary Disease: A Systematic Review |
| title_sort | dupilumab for chronic obstructive pulmonary disease a systematic review |
| topic | dupilumab interleukin 4 interleukin 13 eosinophilia chronic obstructive pulmonary disease type 2 inflammation |
| url | https://www.mdpi.com/2673-8449/5/1/5 |
| work_keys_str_mv | AT juliayoung dupilumabforchronicobstructivepulmonarydiseaseasystematicreview AT taylorspisany dupilumabforchronicobstructivepulmonarydiseaseasystematicreview AT coreymguidry dupilumabforchronicobstructivepulmonarydiseaseasystematicreview AT jisoohong dupilumabforchronicobstructivepulmonarydiseaseasystematicreview AT jessicale dupilumabforchronicobstructivepulmonarydiseaseasystematicreview AT edwardelrassi dupilumabforchronicobstructivepulmonarydiseaseasystematicreview AT paulmboylan dupilumabforchronicobstructivepulmonarydiseaseasystematicreview |